Amgen’s KRAS drug Lumakras clinches FDA green light in colorectal cancer

Amgen’s Lumakras has secured an FDA approval in combination with the drugmaker’s Vectibix for a subset of patients with metastatic colorectal cancer, marking a positive change for the selective KRAS G12C inhibitor after a spate ...